CN Patent

CN111635404B — 一种度维尼西的制备方法

Assigned to Suzhou Miracpharma Technology Co Ltd · Expires 2023-11-07 · 3y expired

What this patent protects

本发明揭示了一种度维尼西(Duvelisib)的制备方法，其步骤包括：以2‑氯‑6‑甲基‑N‑苯基苯甲酰胺为起始原料，依次经过氧化、环氧化、重排、环合、亚胺化和手性催化下的氢化反应，生成目标化合物度维尼西。该制备方法原料易得，条件温和，安全环保，为度维尼西的工业化生产提供了一条新的途径。

USPTO Abstract

本发明揭示了一种度维尼西(Duvelisib)的制备方法，其步骤包括：以2‑氯‑6‑甲基‑N‑苯基苯甲酰胺为起始原料，依次经过氧化、环氧化、重排、环合、亚胺化和手性催化下的氢化反应，生成目标化合物度维尼西。该制备方法原料易得，条件温和，安全环保，为度维尼西的工业化生产提供了一条新的途径。

Drugs covered by this patent

Patent Metadata

Patent number
CN111635404B
Jurisdiction
CN
Classification
—
Expires
2023-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Miracpharma Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.